Komori
Eisai (4523) · InitiativeFirst stated

Transfer of Rights to Receive Economic Benefits from elacestrant

First written in FY2024-Q1. . Latest entry: FY2024-Q1.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Proceeds from the transfer of the right to receive economic returns from elacestrantA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2024-Q1First statedAnnual report

    「売上収益は、抗がん剤「レンビマ」および不眠症治療剤「デエビゴ」（英名「Dayvigo」）が引き続き伸長したことに加え、選択的エストロゲン受容体分解薬elacestrant（一般名）に係る経済的収益受領権の譲渡に伴う一時金の受領などにより、増収となりました。」

    elacestrantに係る経済的収益受領権を譲渡し、一時金を受領したことが第1四半期の増収要因として初めて記載された。相手先や一時金額は本文で示されていない。
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Eisai yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Transfer of Rights to Receive Economic Benefits from elacestrant | Eisai Co.,Ltd. (4523) | Komori